Loading clinical trials...
Loading clinical trials...
The purpose of this study is to see if treatment with AZD4818 for four weeks is tolerable, safe and effective in treating COPD and, if so, how it compares with placebo.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
AstraZeneca
NCT07307781 · Chronic Obstructive Pulmonary Disease (COPD)
NCT07509606 · Chronic Obstructive Pulmonary Disease (COPD), Whole Body Vibration
NCT07451977 · Chronic Respiratory Failure, Hypoxemia, and more
NCT07082738 · Chronic Obstructive Pulmonary Disease (COPD)
NCT07477600 · Chronic Obstructive Pulmonary Disease (COPD)
Research Site
Hvidovre
Research Site
København NV
Research Site
Odense C
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions